Free Trial

Twist Bioscience Co. (NASDAQ:TWST) Stock Holdings Decreased by Gotham Asset Management LLC

Twist Bioscience logo with Medical background

Gotham Asset Management LLC reduced its position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 39.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 16,925 shares of the company's stock after selling 10,813 shares during the period. Gotham Asset Management LLC's holdings in Twist Bioscience were worth $787,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Barclays PLC grew its stake in shares of Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after buying an additional 104,420 shares during the period. Avanza Fonder AB purchased a new stake in shares of Twist Bioscience during the 4th quarter valued at $1,059,000. Principal Financial Group Inc. grew its stake in shares of Twist Bioscience by 67.5% during the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock valued at $9,301,000 after buying an additional 82,953 shares during the period. Vanguard Group Inc. grew its stake in shares of Twist Bioscience by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after buying an additional 189,791 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Twist Bioscience by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock valued at $1,761,000 after buying an additional 9,722 shares during the period.

Analyst Upgrades and Downgrades

TWST has been the subject of several research reports. Barclays lowered their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. JPMorgan Chase & Co. reduced their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Robert W. Baird reduced their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, Guggenheim restated a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Twist Bioscience presently has a consensus rating of "Moderate Buy" and a consensus target price of $50.40.

Check Out Our Latest Stock Report on Twist Bioscience

Insiders Place Their Bets

In other news, SVP Paula Green sold 918 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the sale, the senior vice president now owns 130,912 shares of the company's stock, valued at approximately $5,355,609.92. The trade was a 0.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emily M. Leproust sold 2,402 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the sale, the chief executive officer now directly owns 662,692 shares of the company's stock, valued at $27,110,729.72. The trade was a 0.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,011 shares of company stock worth $951,499 in the last quarter. 3.01% of the stock is owned by corporate insiders.

Twist Bioscience Stock Up 0.4%

TWST stock traded up $0.10 during trading on Friday, reaching $28.26. The stock had a trading volume of 781,842 shares, compared to its average volume of 977,464. Twist Bioscience Co. has a 1-year low of $27.12 and a 1-year high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.69 billion, a P/E ratio of -8.36 and a beta of 2.54. The firm has a fifty day moving average price of $36.71 and a 200 day moving average price of $42.83.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. On average, equities analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

(Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Read More

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Should You Invest $1,000 in Twist Bioscience Right Now?

Before you consider Twist Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.

While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns
NVIDIA’s Secret Picks? 3 Stocks Rising With the AI Giant

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines